---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-23-015159"
form_type: "8-K"
ticker: "SSKN"
cik: "0001051514"
company_name: "STRATA Skin Sciences, Inc."
filed_at: "2023-03-31T23:59:59+00:00"
generated_at: "2026-06-17T07:33:12.657006+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# STRATA Skin Sciences reports record Q4 revenue of $10.6M; FY 2023 guidance $38M-$40M

## Summary
- Q4 2022 revenue $10.6M (+17% YoY); full-year revenue $36.2M (+21% YoY).
- Net loss narrowed to $0.2M in Q4 ($0.005/share) vs $0.8M loss in Q4 2021; full-year net loss $5.5M vs $2.7M.
- Domestic installed base of 909 XTRAC devices; acquired TheraClearX acne device in Jan 2022.
- FY 2023 revenue guidance of $38M-$40M; entered Mexican market with distribution agreement.

## SEC filing metadata
- accession: 0001140361-23-015159
- form_type: 8-K
- ticker: SSKN
- cik: 0001051514
- company_name: STRATA Skin Sciences, Inc.
- filed_at: 2023-03-31T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1051514/000114036123015159/0001140361-23-015159-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1051514/000114036123015159/brhc10050694_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-23-015159
- JSON: https://secwatch.observer/filing/0001140361-23-015159.json
- Plain text: https://secwatch.observer/filing/0001140361-23-015159.txt

## Key facts
- Earnings Releases
  STRATA Skin Sciences, Inc. reported the fourth fiscal quarter and full year ended December 31, 2022 results: revenue $10.6 million, net income Net loss for the fourth quarter of 2022 was $0.2 million, or a loss of $0.005 per basic and diluted common share, EPS loss of $0.005 per basic and diluted common share. Guidance raised.
  - Period: the fourth fiscal quarter and full year ended December 31, 2022
  - Revenue: $10.6 million
  - Net income: Net loss for the fourth quarter of 2022 was $0.2 million, or a loss of $0.005 per basic and diluted common share
  - EPS: loss of $0.005 per basic and diluted common share
  - Guidance: raised
  - Result: reported results
  source text: results for the fourth quarter and full year ended December 31, 2022. Fourth Quarter 2022 and Recent Business Highlights: ● Revenue in the fourth quarter of 2022 was a record $10.6 million, an increase of 17% over the fourth quarter of 2021 ○ Global recurring revenue was $6.5 million ○ Gross domestic recurring billings were $5.8 million ● Revenue for the full year
  evidence_url: https://www.sec.gov/Archives/edgar/data/1051514/000114036123015159/0001140361-23-015159-index.htm
- Earnings Releases
  STRATA Skin Sciences, Inc. reported the fiscal year ended December 31, 2022 results: revenue $36.2 million, net income Net loss for the full year 2022 was $5.5 million, or a loss of $0.16 per basic and diluted common share, EPS loss of $0.16 per basic and diluted common share. Guidance raised.
  - Period: the fiscal year ended December 31, 2022
  - Revenue: $36.2 million
  - Net income: Net loss for the full year 2022 was $5.5 million, or a loss of $0.16 per basic and diluted common share
  - EPS: loss of $0.16 per basic and diluted common share
  - Guidance: raised
  - Result: reported results
  source text: Revenues for the full year 2022 were $36.2 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1051514/000114036123015159/0001140361-23-015159-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.